Scarica l'app Stockscreener
59.44
1.95%
-1.18
Dopo l'orario di chiusura:
59.00
-0.44
-0.74%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
RTRX5376243 Bond Profile: Coupon and Redemption - TradingView
TVTX Maintained by Guggenheim -- Price Target Raised to $89.00 - GuruFocus
Guggenheim raises Travere Therapeutics stock price target on patent By Investing.com - Investing.com Canada
Understanding the Setup: (TVTX) and Scalable Risk - news.stocktradersdaily.com
Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI - marketscreener.com
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis - BioSpace
Travere receives patent allowance for FILSPARI use in FSGS - Investing.com
Travere TherapeuticsReceives USPTO Notice Of Allowance For Filspari Patent In FSGS - TradingView
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Stocktwits
Travere Therapeutics, Inc. (TVTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Travere Therapeutics (TVTX) Sets CEO Handover For December 2026 - Yahoo Finance
Why Everyone Is Watching Travere Therapeutics (TVTX) Today - simplywall.st
Travere Therapeutics appoints new CEO Bradley Campbell - The Globe and Mail
Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today - finance.yahoo.com
TVTX Reiterated by Wedbush -- Price Target Maintained at $76.00 - GuruFocus
Travere Therapeutics Names Bradley Campbell CEO - Contract Pharma
Wedbush reiterates Outperform rating on Travere Therapeutics, $76 price target - TradingView
HC Wainwright & Co. reiterates Buy rating on Travere Therapeutics, $67 price target - TradingView
TVTX Looks 64.1% Overvalued on GF Value™ - GuruFocus
Travere Therapeutics Announces Planned Chief Executive Officer Transition - BioSpace
Travere Therapeutics stock falls amid CEO transition news By Investing.com - Investing.com Nigeria
Travere Therapeutics Names Bradley Campbell CEO Effective December 1, 2026 - Minichart
Travere Therapeutics stock falls amid CEO transition news - Investing.com
Travere Therapeutics CEO Eric Dube to step down in December By Investing.com - Investing.com Nigeria
Travere Therapeutics President and CEO Eric Dube Plans to Step Down - marketscreener.com
Travere Therapeutics CEO Eric Dube to step down in December - Investing.com India
Travere Therapeutics, Inc. Announces CEO Changes, Effective December 1, 2026 - marketscreener.com
Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum - ChartMill
Travere Therapeutics CFO Cline Christopher R. Executes Options and Sells Shares on September 15, 2026 - Kalkine Media
Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics Insider Sold Shares Worth $2,337,695, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics Insider Sold Shares Worth $13,135,397, According to a Recent SEC Filing - marketscreener.com
Travere therapeutics chief research officer William Rote sells $13.1m in stock - Investing.com Canada
Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock - Investing.com Australia
Travere Therapeutics CLO Elizabeth Reed sells $2.34m in stock By Investing.com - Investing.com Australia
Travere Therapeutics CFO Cline sells $3.1m in company stock By Investing.com - Investing.com Australia
Travere therapeutics CEO Eric Dube sells $25.4m in shares - Investing.com
Travere Therapeutics CFO Cline sells $3.1m in company stock - Investing.com
Travere therapeutics CEO Eric Dube sells $25.4m in shares By Investing.com - Investing.com Canada
Jula Inrig Sells 44,674 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) EVP Sells $10,955,439.31 in Stock - MarketBeat
Travere Therapeutics SVP sells $335k in stock - Investing.com
Travere Therapeutics SVP sells $335k in stock By Investing.com - Investing.com Canada
Travere (TVTX) R&D boss sells stock under 10b5-1 plan—how big was the trade? - Stock Titan
Insider at Travere (NASDAQ: TVTX) sells stock under preset trading plan - Stock Titan
Travere Therapeutics (TVTX) chief accounting officer sells 5,375 shares under preset plan - Stock Titan
Travere Therapeutics (TVTX) research chief unloads shares under a preset plan, with the sale size now disclosed - Stock Titan
Planned $6.9M stock sale in Travere (NASDAQ: TVTX) - Stock Titan
Travere (NASDAQ: TVTX) insider plans more stock sales after multi-million plan trades - Stock Titan
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum - Yahoo Finance
Travere Therapeutics, Inc.Common Stock (Nasdaq:TVTX) Price Chart - The Chronicle-Journal
Travere CFO (NASDAQ: TVTX) sells 50K shares in pre-set trading plan - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) officer plans 112,850-share sale after recent 96,198-share trade - Stock Titan
Travere Therapeutics (TVTX) insider plans 172,717-share sale after option exercise - Stock Titan
After $6M sale, Travere (NASDAQ: TVTX) insider plans another stock move - Stock Titan
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Travere Therapeutics (NASDAQ: TVTX) officer may sell shares after cashing in options - Stock Titan
Officer at Travere Therapeutics (TVTX) moves to sell tens of thousands of shares - Stock Titan
Insider plans 39,576-share sale at Travere Therapeutics (NASDAQ: TVTX) in 2026 - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) shareholder Eric Dube plans 95,666-share sale in September 2026 - Stock Titan
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):